Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an ...
– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months– – Combination studies with RAS(ON) inhibitors ongoing, data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback